What is ANBIO BIOTECHNOLOGY's earnings per share (EPS)?

ANBIO BIOTECHNOLOGY (NNNN) reported diluted earnings per share of $0.15 for fiscal year 2025. This represents a 162.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ANBIO BIOTECHNOLOGY Financials

NNNN

Source SEC Filings (10-K/10-Q) Updated Apr 7, 2026 Currency USD FYE April

This page shows ANBIO BIOTECHNOLOGY (NNNN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 80/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

100

ANBIO BIOTECHNOLOGY has an operating margin of 66.7%, meaning the company retains $67 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from 24.4% the prior year.

Growth

ANBIO BIOTECHNOLOGY's revenue grew 5.6% year-over-year to $8.6M, a solid pace of expansion. This earns a growth score of 43/100.

Leverage

100

ANBIO BIOTECHNOLOGY carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 344.31, ANBIO BIOTECHNOLOGY holds $344.31 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

ANBIO BIOTECHNOLOGY's ROE of 21.2% shows moderate profitability relative to equity, earning a score of 58/100. This is up from 13.8% the prior year.

Altman Z-Score Safe

7841.92

ANBIO BIOTECHNOLOGY scores 7841.92, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.1B) relative to total liabilities ($88K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

4/9

ANBIO BIOTECHNOLOGY passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

-1.05x

For every $1 of reported earnings, ANBIO BIOTECHNOLOGY generates $-1.05 in operating cash flow (-$6.7M OCF vs $6.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$8.6M

YoY+5.6%

ANBIO BIOTECHNOLOGY generated $8.6M in revenue in fiscal year 2025. This represents an increase of 5.6% from the prior year.

EBITDA

N/A

Net Income

$6.4M

YoY+169.9%

ANBIO BIOTECHNOLOGY reported $6.4M in net income in fiscal year 2025. This represents an increase of 169.9% from the prior year.

EPS (Diluted)

$0.15

YoY+162.5%

ANBIO BIOTECHNOLOGY earned $0.15 per diluted share (EPS) in fiscal year 2025. This represents an increase of 162.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$7.8M

YoY-34.0%

ANBIO BIOTECHNOLOGY held $7.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

44M

ANBIO BIOTECHNOLOGY had 44M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

87.2%

YoY+15.3pp

ANBIO BIOTECHNOLOGY's gross margin was 87.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 15.3 percentage points from the prior year.

Operating Margin

66.7%

YoY+42.3pp

ANBIO BIOTECHNOLOGY's operating margin was 66.7% in fiscal year 2025, reflecting core business profitability. This is up 42.3 percentage points from the prior year.

Net Margin

74.1%

YoY+45.1pp

ANBIO BIOTECHNOLOGY's net profit margin was 74.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 45.1 percentage points from the prior year.

Return on Equity

21.2%

YoY+7.4pp

ANBIO BIOTECHNOLOGY's ROE was 21.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 7.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$201K

YoY-55.7%

ANBIO BIOTECHNOLOGY invested $201K in research and development in fiscal year 2025. This represents a decrease of 55.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

NNNN Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	$8.6M+5.6%	$8.2M+21.9%	$6.7M-71.5%	$23.5M
Cost of Revenue	$1.1M-52.0%	$2.3M-31.4%	$3.4M-69.5%	$11.0M
Gross Profit	$7.5M+28.2%	$5.9M+75.1%	$3.4M-73.2%	$12.6M
R&D Expenses	$201K-55.7%	$454K+237.2%	$135K-32.6%	$200K
SG&A Expenses	$1.6M-54.2%	$3.4M+171.6%	$1.3M-41.6%	$2.2M
Operating Income	$5.8M+189.1%	$2.0M+1.8%	$2.0M-80.8%	$10.2M
Interest Expense	N/A	N/A	N/A	$8K
Income Tax	N/A	N/A	N/A	N/A
Net Income	$6.4M+169.9%	$2.4M+5.3%	$2.3M-77.5%	$10.0M
EPS (Diluted)	$0.15+162.5%	$0.06-46.7%	$0.10-100.0%	$100112.00

Metric	Q3'25	Q3'24
Revenue	N/A	N/A
Cost of Revenue	N/A	N/A
Gross Profit	N/A	N/A
R&D Expenses	N/A	N/A
SG&A Expenses	N/A	N/A
Operating Income	N/A	N/A
Interest Expense	N/A	N/A
Income Tax	N/A	N/A
Net Income	N/A	N/A
EPS (Diluted)	N/A	N/A

NNNN Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$30.2M+59.8%	$18.9M+19.7%	$15.8M	N/A
Current Assets	$30.2M+63.2%	$18.5M+17.7%	$15.7M	N/A
Cash & Equivalents	$7.8M-34.0%	$11.8M+21.4%	$9.7M+36.4%	$7.1M
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	$3.7M+243.3%	$1.1M-43.5%	$1.9M	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$88K-94.9%	$1.7M+74.2%	$993K	N/A
Current Liabilities	$88K-94.9%	$1.7M+74.2%	$993K	N/A
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	$30.2M+75.4%	$17.2M+16.0%	$14.8M+18.1%	$12.5M
Retained Earnings	$23.6M+37.3%	$17.2M+16.0%	$14.8M	N/A

Metric	Q3'25	Q3'24
Total Assets	$18.9M+19.7%	$15.8M
Current Assets	$18.5M+17.7%	$15.7M
Cash & Equivalents	$11.8M+21.4%	$9.7M
Inventory	N/A	N/A
Accounts Receivable	$1.1M-43.5%	$1.9M
Goodwill	N/A	N/A
Total Liabilities	$1.7M+74.2%	$993K
Current Liabilities	$1.7M+74.2%	$993K
Long-Term Debt	N/A	N/A
Total Equity	$17.2M+16.0%	$14.8M
Retained Earnings	$17.2M+16.0%	$14.8M

NNNN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	-$6.7M-423.9%	$2.1M+131.6%	$898K-79.8%	$4.4M
Capital Expenditures	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A
Investing Cash Flow	-$4.2M-1346.7%	$337K-80.5%	$1.7M+213.2%	-$1.5M
Financing Cash Flow	$6.9M+2116.1%	-$345K-704.5%	-$43K	N/A
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24
Operating Cash Flow	N/A	N/A
Capital Expenditures	N/A	N/A
Free Cash Flow	N/A	N/A
Investing Cash Flow	N/A	N/A
Financing Cash Flow	N/A	N/A
Dividends Paid	N/A	N/A
Share Buybacks	N/A	N/A

NNNN Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	87.2%+15.3pp	71.9%+21.8pp	50.1%-3.3pp	53.4%
Operating Margin	66.7%+42.3pp	24.4%-4.8pp	29.2%-14.1pp	43.3%
Net Margin	74.1%+45.1pp	29.0%-4.6pp	33.6%-8.9pp	42.5%
Return on Equity	21.2%+7.4pp	13.8%-1.4pp	15.2%-64.6pp	79.8%
Return on Assets	21.2%+8.6pp	12.5%-1.7pp	14.2%	N/A
Current Ratio	344.31+333.6	10.71-5.1	15.86	N/A
Debt-to-Equity	0.00-0.1	0.10+0.0	0.07	N/A
FCF Margin	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24
Gross Margin	N/A	N/A
Operating Margin	N/A	N/A
Net Margin	N/A	N/A
Return on Equity	N/A	N/A
Return on Assets	N/A	N/A
Current Ratio	10.71-5.1	15.86
Debt-to-Equity	0.10+0.0	0.07
FCF Margin	N/A	N/A

Similar Companies

Atricure ATRC

$1.5B

Staar Surg STAA

$1.0B

Azenta Inc AZTA

$1.0B

Biolife Solutions Inc BLFS

$930.7M

KESTRA MED TECHNOLOGIES LTD KMTS

$1.1B

Frequently Asked Questions

What is ANBIO BIOTECHNOLOGY's annual revenue?

ANBIO BIOTECHNOLOGY (NNNN) reported $8.6M in total revenue for fiscal year 2025. This represents a 5.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ANBIO BIOTECHNOLOGY's revenue growing?

ANBIO BIOTECHNOLOGY (NNNN) revenue grew by 5.6% year-over-year, from $8.2M to $8.6M in fiscal year 2025.

Is ANBIO BIOTECHNOLOGY profitable?

Yes, ANBIO BIOTECHNOLOGY (NNNN) reported a net income of $6.4M in fiscal year 2025, with a net profit margin of 74.1%.

What is ANBIO BIOTECHNOLOGY's gross margin?

ANBIO BIOTECHNOLOGY (NNNN) had a gross margin of 87.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is ANBIO BIOTECHNOLOGY's operating margin?

ANBIO BIOTECHNOLOGY (NNNN) had an operating margin of 66.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is ANBIO BIOTECHNOLOGY's net profit margin?

ANBIO BIOTECHNOLOGY (NNNN) had a net profit margin of 74.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is ANBIO BIOTECHNOLOGY's return on equity (ROE)?

ANBIO BIOTECHNOLOGY (NNNN) has a return on equity of 21.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is ANBIO BIOTECHNOLOGY's operating cash flow?

ANBIO BIOTECHNOLOGY (NNNN) generated -$6.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are ANBIO BIOTECHNOLOGY's total assets?

ANBIO BIOTECHNOLOGY (NNNN) had $30.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does ANBIO BIOTECHNOLOGY spend on research and development?

ANBIO BIOTECHNOLOGY (NNNN) invested $201K in research and development during fiscal year 2025.

How many shares does ANBIO BIOTECHNOLOGY have outstanding?

ANBIO BIOTECHNOLOGY (NNNN) had 44M shares outstanding as of fiscal year 2025.

What is ANBIO BIOTECHNOLOGY's current ratio?

ANBIO BIOTECHNOLOGY (NNNN) had a current ratio of 344.31 as of fiscal year 2025, which is generally considered healthy.

What is ANBIO BIOTECHNOLOGY's debt-to-equity ratio?

ANBIO BIOTECHNOLOGY (NNNN) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ANBIO BIOTECHNOLOGY's return on assets (ROA)?

ANBIO BIOTECHNOLOGY (NNNN) had a return on assets of 21.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is ANBIO BIOTECHNOLOGY's cash runway?

Based on fiscal year 2025 data, ANBIO BIOTECHNOLOGY (NNNN) had $7.8M in cash against an annual operating cash burn of $6.7M. This gives an estimated cash runway of approximately 14 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is ANBIO BIOTECHNOLOGY's Altman Z-Score?

ANBIO BIOTECHNOLOGY (NNNN) has an Altman Z-Score of 7841.92, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is ANBIO BIOTECHNOLOGY's Piotroski F-Score?

ANBIO BIOTECHNOLOGY (NNNN) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ANBIO BIOTECHNOLOGY's earnings high quality?

ANBIO BIOTECHNOLOGY (NNNN) has an earnings quality ratio of -1.05x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is ANBIO BIOTECHNOLOGY?

ANBIO BIOTECHNOLOGY (NNNN) scores 80 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.